Podcast
on demand
09
Nov
2022
09
00
CET
Tumour sites
ILD and HER2 targeted agents

This session is part of the SPCC Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project. Following the Task Force - held in 2022 - the third phase of the project will focus on short contributions on the topic by Task Force experts.

 

 

Speakers
Discussant
Rugo Hope
Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
Expert
Dieras Veronique
Senior Medical Oncologist at Centre Eugène-Marquis, Rennes, France
This material is part of Educational Project:
2022 - Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project